Virology News and Research

Latest Virology News and Research

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

There has been substantial mystery surrounding the origins of Chronic Fatigue Syndrome (CFS), a condition affecting as many as four million Americans and marked by symptoms that include a sense of weariness that sleep does not improve and difficulty with memory and concentration.

6 Apr 2011

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Aragen Bioscience, Inc., today announced it is a subcontractor on a National Institute of Allergy and Infectious Diseases contract for the preclinical development of monoclonal antibodies for the prevention and treatment of infectious diseases.

6 Apr 2011

LA County introduces new HIV/AIDS advertising campaign

The Los Angeles County Department of Public Health, Office of AIDS Programs and Policy announces today the launch of its multi-media advertising campaign aimed at fighting the spread of HIV and AIDS in Los Angeles County. Beginning this week, the bi-lingual Erase Doubt campaign will be seen throughout LA County on bustails, at community events, in bars and nightclubs, and online.

6 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Novavax, Inc. announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza. The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

5 Apr 2011

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Scientists at Polytechnic Institute of New York University (NYU-Poly) and at the NYU College of Dentistry have discovered a biochemical version of a principle well known among confectioners. Call it the "peanut butter and chocolate" rule: Sometimes two things work better together than alone.

5 Apr 2011

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Oral cancer more common among Americans with HPV16 viral infections

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Oral Cancer Awareness Week aims to educate people regarding importance of early detection

The 2011 Oral Cancer Awareness Week, set for April 11-15, is intended to educate people of all ages and socio-economic levels about the risk factors and symptoms of oral, head and neck cancer and the importance of early detection.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Virology News and Research

Latest Virology News and Research

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

LA County introduces new HIV/AIDS advertising campaign

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Scientists effectively combine two methods used as vehicles to carry DNA into cell nuclei

Study suggests causal link between HSV1 and Alzheimer's disease

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Oral cancer more common among Americans with HPV16 viral infections

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Series of new clinical trials confirm range of viable treatment options for HCV patients

Oral Cancer Awareness Week aims to educate people regarding importance of early detection

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep